2025-10-14 - Analysis Report
Okay, here's an analysis of Merck & Co. Inc. (MRK) based on the data you provided.

## Merck & Co. Inc. (MRK) Analysis

**Company Overview:** Merck & Co. Inc. is a global pharmaceutical company that develops and markets a wide range of healthcare products.

### 1. Performance vs. S&P 500 (VOO)

**Key Numbers:**

*   **MRK Cumulative Return:** 1.33%
*   **VOO Cumulative Return:** 96.68%
*   **Return Spread:**
    *   **Current:** -96.65%
    *   **Range (Min/Max):** -103.9% / 23.9%
    *   **Relative Spread Position:** 5.6%

**Analysis:**

MRK has significantly underperformed the S&P 500 (VOO) over the observed period. The cumulative return of MRK is only 1.33% compared to VOO's 96.68%. The current spread is -96.65%, which is near the lowest end of its historical range. The relative spread position of 5.6% indicates that MRK's underperformance is near its worst relative to the S&P 500 within the observed timeframe.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha    | Beta    | Cap(B) |
|------------|---------|--------|----------|---------|--------|
| 2015-2017  | 1.0%    | 68.5%  | -28.0%   | 0.0     | 134.1  |
| 2016-2018  | 36.0%   | 69.8%  | 21.0%    | -0.0    | 182.1  |
| 2017-2019  | 40.0%   | 69.8%  | 18.0%    | 0.3     | 216.8  |
| 2018-2020  | 16.0%   | 79.6%  | -8.0%    | 0.3     | 195.0  |
| 2019-2021  | 2.0%    | 79.6%  | -44.0%   | 0.7     | 191.4  |
| 2020-2022  | 15.0%   | 79.6%  | 16.0%    | 0.7     | 277.1  |
| 2021-2023  | 33.0%   | 79.6%  | 31.0%    | 0.3     | 272.3  |
| 2022-2024  | -4.0%   | 79.6%  | -25.0%   | 0.2     | 248.5  |
| 2023-2025  | -48.0%  | 71.5%  | -109.0%  | 1.4     | 214.1  |

**Analysis:**

*   **CAGR:** Fluctuates significantly, with negative CAGR in recent periods.
*   **MDD:** High Maximum Drawdown (MDD) across all periods indicates significant potential for losses.
*   **Alpha:** Alpha is highly variable. The recent period (2023-2025) shows a significant negative alpha, indicating underperformance relative to the benchmark.
*   **Beta:** Beta values are generally low, suggesting MRK has historically been less sensitive to market movements. However, the recent beta of 1.4 suggests increased sensitivity.
*   **Cap:** Market capitalization fluctuates over time.

### 2. Recent Stock Price Movement

**Key Numbers:**

*   **Current Price:** \$85.70
*   **Previous Close:** \$85.99
*   **Change:** -0.34 (-0.40%)
*   **5-Day Moving Average:** 86.45
*   **20-Day Moving Average:** 83.77
*   **60-Day Moving Average:** 83.24

**Analysis:**

The stock price has slightly decreased recently. The 5-day moving average is above the 20-day and 60-day moving averages, suggesting a short-term upward trend. However, the recent price decrease indicates a potential pullback.

### 3. Technical Indicators

**Key Numbers:**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment)
*   **RSI:** 65.18 (Approaching overbought)
*   **PPO:** 0.28
*   **Hybrid Signal:** Buy 100% (Very Safe)
*   **20-Day Relative Spread Change:** -3.2 (Short-term decline)
*   **Expected Return:** -113%

**Analysis:**

*   **MRI:** Indicates a medium level of investment risk.
*   **RSI:** Suggests the stock is approaching overbought territory, which could indicate a potential pullback.
*   **PPO:** Positive PPO suggests a slightly bullish trend.
*   **Hybrid Signal:** Contradictory signals. This suggests buying for safety.
*   **20-Day Relative Spread Change:** Indicates recent underperformance relative to the benchmark.
*   **Expected Return:** Very negative expected return suggests caution for long-term investment.

### 4. Recent News & Significant Events

*   **Keytruda's subcutaneous FDA approval and extended patent:** This is a positive development, as Keytruda is a major revenue driver for Merck.
*   **Merck Completes \$10B Acquisition of Verona Pharma:** The acquisition of Verona Pharma and its COPD drug Ohtuvayre could provide a new growth avenue for Merck.
*   **Analyst Sentiment:** Mixed analyst opinions, with some indicating a strong momentum.

### 4-2. Analyst Opinions

*   **Consensus:** Buy
*   **Mean Rating:** 2.00 (Buy)
*   **Target Price:** \$101.40 (Average)

**Analysis:**

Analysts generally have a positive outlook on Merck, with a consensus "Buy" rating and a target price significantly above the current price.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 매출      |
|------------|------|-----------|
| 2025-08-05 | 1.76 | 15.81 B$  |
| 2025-05-02 | 2.01 | 15.53 B$  |
| 2024-11-06 | 1.25 | 16.66 B$  |
| 2024-08-05 | 2.15 | 16.11 B$  |
| 2025-08-05 | 2.15 | 16.11 B$  |

**Analysis:**

EPS and Revenue are fluctuating. The EPS has varied, and revenue has also seen some fluctuation.

### 6. Financial Information

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-06-30   | \$15.81B   | 77.50%        |
| 2025-03-31   | \$15.53B   | 77.98%        |
| 2024-12-31   | \$15.62B   | 75.50%        |
| 2024-09-30   | \$16.66B   | 75.51%        |
| 2024-06-30   | \$16.11B   | 76.76%        |

**Analysis:**

*   **Revenue:** Revenue has been relatively stable over the past few quarters, ranging from \$15.53B to \$16.66B.
*   **Profit Margin:** Profit margins are high, consistently above 75%, indicating strong profitability.

| Quarter      | Equity     | ROE      |
|--------------|------------|----------|
| 2025-06-30   | \$48.99B   | 9.04%    |
| 2025-03-31   | \$48.34B   | 10.51%   |
| 2024-12-31   | \$46.31B   | 8.08%    |
| 2024-09-30   | \$44.50B   | 7.09%    |
| 2024-06-30   | \$43.58B   | 12.52%   |

**Analysis:**

*   **Equity:** Equity has been increasing steadily.
*   **ROE:** Return on Equity (ROE) fluctuates, but generally indicates good profitability relative to equity.

### 7. Overall Summary

Merck (MRK) is currently showing a mixed picture. While analysts have a generally positive outlook and the company maintains strong profit margins, recent performance has lagged the S&P 500, and technical indicators suggest the stock may be approaching overbought territory. The recent acquisition and the potential expansion of Keytruda's market provide potential catalysts for future growth. However, the negative expected return and the recent underperformance relative to the benchmark warrant caution.
